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Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculi-
tis is a systemic small-vessel vasculitis, wherein, MPO-ANCA plays a critical role in the 
pathogenesis. Neutrophil extracellular traps (NETs) released from activated neutrophils 
are composed of extracellular web-like DNA and antimicrobial proteins, including MPO. 
Diverse stimuli, such as phorbol myristate acetate (PMA) and ligands of toll-like receptors 
(TLR), induce NETs. Although TLR-mediated NET formation can occur with preservation 
of living neutrophilic functions (called vital NETosis), PMA-stimulated neutrophils undergo 
cell death with NET formation (called suicidal NETosis). In the process of suicidal NETosis, 
histones are citrullinated by peptidylarginine deiminase 4 (PAD4). Since this step is 
necessary for decondensation of DNA, PAD4 plays a pivotal role in suicidal NETosis. 
Although NETs are essential for elimination of microorganisms, excessive formation 
of NETs has been suggested to be implicated in MPO-ANCA production. This study 
aimed to determine if pan-PAD inhibitors could suppress MPO-ANCA production in vivo. 
At first, NETs were induced in peripheral blood neutrophils derived from healthy donors 
(1 ×  106/ml) by stimulation with 20  nM PMA with or without 20  μM propylthiouracil 
(PTU), an anti-thyroid drug. We then determined that the in  vitro NET formation was 
inhibited completely by 200 μM Cl-amidine, a pan-PAD inhibitor. Next, we established 
mouse models with MPO-ANCA production. BALB/c mice were given intraperitoneal 
(i.p.) injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks. 
These mice were divided into two groups; the first group was given daily i.p. injection 
of PBS (200 μl/day) (n = 13) and the other group with daily i.p. injection of Cl-amidine 
(0.3 mg/200 μl PBS/day) (n = 7). Two weeks later, citrullination as an indicator of NET 
formation in the peritoneum and serum MPO-ANCA titer was compared between the 
two groups. Results demonstrated that citrullination in the peritoneum was significantly 
reduced in the Cl-amidine-treated mice compared with the vehicle-injected control mice 
(38% reduction). Additionally, the serum MPO-ANCA titer of the Cl-amidine-treated 
mice (32.3 ± 31.0 ng/ml) was significantly lower than that in the vehicle-injected mice 
(132.1 ± 41.6 ng/ml). The collective findings indicate that excessive formation of NETs 
may be implicated in MPO-ANCA production in vivo.
Keywords: MPO-anca-associated vasculitis, MPO-anca, neutrophil extracellular trap, peptidylarginine 
deiminase 4, peptidylarginine deiminase inhibitor
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inTrODUcTiOn
Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis is a systemic small-vessel vasculitis (1). The major target 
antigens of ANCA are myeloperoxidase (MPO) and proteinase 
3 (PR3). Neutrophils primed by pro-inflammatory cytokines, 
such as TNF-α, express MPO and PR3 on the cell surface. ANCA 
bind to the antigens and then activate neutrophils directly and/
or through binding to bystander Fcγ receptors. Consequently, 
the activated neutrophils induce vascular endothelial cell injury 
resulting in the development of small-vessel vasculitis (2, 3). 
ANCA, therefore, play a critical role in the pathogenesis 
of  ANCA-associated vasculitis. Although the mechanism of 
MPO-ANCA production was unknown for a long time, recent 
studies have suggested the involvement of neutrophil extracel-
lular traps (NETs) in the mechanism (4–6).
Neutrophil extracellular traps are firstly reported in 2004 as 
extracellular web-like DNA studded with antimicrobial proteins, 
including MPO, which are released from phorbol myristate acetate 
(PMA)-stimulated neutrophils (7). The PMA-stimulated neutro-
phils undergo cell death with the formation of NETs (8), though 
not all stimuli induce cell death in NET-forming neutrophil (9). It 
has been demonstrated that NET formation can occur with pres-
ervation of living neutrophilic functions, including phagocytosis 
and chemotaxis (10, 11). Currently, NET formation undergoing 
cell death is called suicidal NETosis, whereas that preserves liv-
ing neutrophilic functions is called vital NETosis. NETs can trap 
microorganisms by the extracellular DNA and kill them using 
the antimicrobial proteins. Thus, NETosis is considered as an 
important event in innate immunity. However, excessive NETosis 
can result in vascular endothelial cell injury (12), thrombosis (13, 
14), and impairment of diabetic wound healing (15, 16). In addi-
tion, disordered regulation of NETosis has been suggested to be 
involved in the pathogenesis of autoimmune diseases, including 
systemic lupus erythematosus (SLE) (17) and anti-thyroid drug 
propylthiouracil (PTU)-induced MPO-ANCA-associated vas-
culitis (5). In the last two studies, the possibility of extracellular 
components in persistent NETs recognized as autoantigens by the 
immune system was discussed.
Suicidal NETosis is induced in response to diverse stimuli, 
including PMA (7, 18). These stimuli activate the Raf–mitogen-
activated protein kinase kinase–extracellular signal-regulated 
kinase pathway, NADPH oxidase-dependent production of 
reactive oxygen species, and receptor-interacting protein kinase/
mixed lineage kinase domain-like-mediated signals (19, 20). In 
this pathway, peptidylarginine deiminase 4 (PAD4) yields citrul-
lination of histones, around which DNA coils.
The PAD enzymes convert arginine residues to citrulline in 
a variety of protein substrates (21). Among the PAD family, 
which includes PAD 1–4 and 6, PAD4 is expressed mainly in 
hematopoietic cells, such as neutrophils (22). In the process 
of suicidal NETosis, PAD4-dependent citrullination of his-
tones that yields decondensation of DNA is an essential step 
to mix DNA and intracytoplasmic proteins. This mixture is 
subsequently extruded from the ruptured plasma membrane. 
Accordingly, PAD4 plays a pivotal role in the process of suicidal 
NETosis (23).
In the present study, we aimed to determine if a pan-PAD 
inhibitor, Cl-amidine, could suppress MPO-ANCA production 
in vivo. For this purpose, we attempted to generate novel mouse 
models of MPO-ANCA-associated vasculitis according to our 
previous protocol utilized for establishment of a rat model of this 
disease (5). The mouse models would be more useful models that 
require lower doses of reagents than the rat model.
MaTerials anD MeThODs
human neutrophil isolation
Human peripheral blood neutrophils were obtained from healthy 
volunteers by density centrifugation using Polymorphprep 
(Axis-Shield, Dundee, Scotland) according to the manufacturer’s 
instructions.
neT induction In Vitro
The in  vitro NET induction was conducted similarly to our 
earlier study (5). In brief, human peripheral blood neutrophils 
were re-suspended in RPMI 1640 medium supplemented with 
5% fetal bovine serum and then seeded in wells of 4-well chamber 
slides (Thermo Fisher Scientific, Yokohama, Japan) (1 × 106/ml). 
After incubation for 30 min at 37°C, the cells were exposed to 
0 or 20 nM PMA (Sigma-Aldrich, St. Louis, MO, USA) with or 
without 20 μM PTU (Chugai Pharmaceutical, Tokyo, Japan) and 
incubated for another 2 h at 37°C.
PaD inhibitor administration In Vitro
Fifteen minutes prior to the PMA/PTU administration, 200 μM 
Cl-amidine (Calbiochem, San Diego, CA, USA), a pan-PAD 
inhibitor, was added alternately into the wells. The concentration 
of Cl-amidine was adopted according to the previous report (24).
Quantification of neTs In Vitro
After 2 h of incubation, the medium containing the reagents was 
removed, and the remaining cells were washed with PBS followed 
by fixation with 4% paraformaldehyde for 15 min. Thereafter, the 
specimens were made to react with 5 μg/ml of rabbit anti-human 
citrullinated histone 3 polyclonal antibody (Abcam, Cambridge, 
UK) for 60 min at room temperature. After removal of unbound 
antibody, the specimens were next allowed to react with 1:500 
dilution of Alexa Fluor 594-conjugated goat anti-rabbit IgG anti-
body (Invitrogen, Tokyo, Japan) for 60 min at room temperature. 
After washing with PBS, the specimens were finally mounted with 
the 4′, 6-diamidino-2-phenylindole (DAPI)-containing solution 
(Sigma-Aldrich). NET formation was observed under a fluores-
cent microscope and was quantified by counting the citrullinated 
histone 3-positive cells per × 100 power field of view. Data from 
five random fields of view (×100) were subjected to the quantita-
tive analysis.
establishment of Mouse Models with 
MPO-anca Production
BALB/c, New Zealand White (NZW), C57BL/6N (B6/N), 
C57BL/6J (B6/J), and DBA mice (14-week-old female) were 
purchased from Clea Japan (Tokyo, Japan). The mice were given 
FigUre 1 | effect of cl-amidine on neT induction in vitro. Human 
peripheral blood neutrophils were seeded in wells of 4-well chamber slides 
(1 × 106/ml). After incubation for 30 min at 37°C, the cells were exposed to 0 
or 20 nM PMA with or without 20 μM PTU. Fifteen minutes prior to PMA/PTU 
administration, 200 μM Cl-amidine was added alternately into the wells. After 
2 h of incubation at 37°C, the medium containing the reagents was removed, 
and the remaining cells were washed with PBS followed by fixation with 4% 
paraformaldehyde for 15 min. Thereafter, immunofluorescent staining for 
citrullinated histone 3 was carried out followed by mounting with the 
DAPI-containing solution. Representative photos (a). Red, citrullinated 
histone 3; Blue: DNA (original magnification: ×400). Quantification of NET 
formation (B). NET formation was quantified by counting the citrullinated 
histone 3-positive cells per × 100 power field of view. Data from five random 
fields of view (×100) were subjected to quantitative analysis. **p < 0.01 in 
Mann–Whitney U-test.
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intraperitoneal (i.p.) injection of PMA (50 ng at days 0 and 7) 
and oral administration of PTU dissolved in 5% glucose water for 
4 weeks (n = 5/strain). Since preliminary experiments revealed 
that each mouse ingested at least 2.5 ml of the drug-containing 
glucose water, the concentration of PTU was set as 1 mg/ml in 
order to administer exactly 2.5 mg PTU per day. These mice were 
maintained under specific pathogen-free condition in accordance 
with the guidelines for the care and use of laboratory animals in 
Hokkaido University (Permission No. 12-0077).
laboratory Data
Mouse urine was collected during the last 24 h using metabolic 
cages. Blood samples were obtained at days 14 and 28. Hematuria 
was assessed by dipsticks (Siemens Healthcare, Tokyo, Japan). 
Biochemical examinations for blood nitrogen urea (BUN) and 
creatinine (Cr) were performed at Daiichi Kishimoto Clinical 
Laboratory (Sapporo, Japan). Serum titer of MPO-ANCA was 
determined by enzyme-linked immunosorbent assay (ELISA) at 
A-CLIP Institute (Chiba, Japan).
histological evaluation
The lungs, kidneys, and peritoneal tissues were obtained at day 28 
and then fixed in 10% formalin. The pulmonary and renal sections 
were subjected to hematoxylin and eosin staining. The sections of 
the peritoneal tissues were subjected to immunohistochemistry 
for citrullinated histone 3 as described previously (25, 26).
PaD inhibitor administration In Vivo
BALB/c mice (14-week-old female) were given i.p. injection 
of PMA (50  ng at days 0 and 7) and oral PTU (2.5  mg/day, 
aforementioned protocol) for 2 weeks. These mice were divided 
into two groups. The first group was given daily i.p. injection of 
PBS (200 μl/day) (n =  13). The second group was given daily 
i.p. injection of Cl-amidine (0.3  mg/200 μl PBS/day) (n =  7). 
The dose of Cl-amidine was adopted according to the previous 
report (27). Each mouse was administered at least 10  mg/kg 
of Cl-amidine per day. Mouse urine was collected during the 
last 24 h using metabolic cages. Blood and tissue samples were 
obtained at day 14.
statistical analysis
The in vitro data were presented as mean ± standard deviation 
(SD) values obtained from experiments repeated for at least five 
times. The in vivo data were also presented as mean ± SD values. 
Mann–Whitney U-tests were applied for statistical evaluation 
with StatPlus software. P-values of <0.05 were regarded as sta-
tistically significant.
resUlTs
effect of PaD inhibitor on neT induction 
In Vitro
Human peripheral blood neutrophils were exposed to 0 or 20 nM 
PMA with or without 20 μM PTU. Fifteen minutes prior to PMA/
PTU exposure, the neutrophils were treated with or without 
200 μM Cl-amidine. Stimulation without PMA did not induce 
NETs (data not shown). It has been also determined that 200 μM 
of Cl-amidine did not affect the viability of neutrophils in vitro 
(Figure S1 in Supplementary Material).
The neutrophils stimulated by 20  nM PMA alone formed 
extended NETs, whereas neutrophils stimulated by 20  nM 
PMA plus 20  μM PTU formed non-extended round-shaped 
NETs (Figure 1A). These findings corresponded with our ear-
lier observations (5) and suggested that PTU yielded abnormal 
conformation of NETs induced by PMA. Although the morphol-
ogy of NETs was different, both stimuli (PMA alone and PMA 
plus PTU) were shown to induce citrullination of histone 3 (5). 
Therefore, PAD4 was likely involved in the NET induction by 
these stimuli. As expected, the pan-PAD inhibitor, Cl-amidine 
(200 μM) inhibited the NET formation induced by both PMA 
alone and PMA plus PTU in vitro (Figures 1A,B). Furthermore, 
FigUre 2 | establishment of mouse models with MPO-anca 
production. Experimental protocol (a). BALB/c, NZW, B6/N, B6/J, and DBA 
mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 
and 7) and oral PTU (2.5 mg/day) for 4 weeks (n = 5/strain, p.o.: Per Os). 
Mouse urine was collected during the last 24 h using metabolic cages, and 
then hematuria was assessed by dipsticks. Blood samples were obtained at 
days 14 and 28, and then the concentrations of BUN and Cr were 
determined. The lungs, kidneys, and peritoneal tissues were obtained at day 
28. Serum titers of MPO-ANCA determined by ELISA were shown with the 
results of the urinalysis and concentrations of Cr in the serum (B). The normal 
limit of serum Cr level is 0.4 mg/dl.
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these findings suggest that Cl-amidine can inhibit not only the 
formation of PMA-induced conventional (extended) NETs but 
also PTU-mediated unconventional (non-extended round-
shaped) NETs.
establishment of Mouse Models 
with MPO-anca Production
In our earlier study, WKY rats were employed to establish an 
animal model of MPO-ANCA-associated vasculitis (5). In this 
study, we attempted to establish novel mouse models of MPO-
ANCA-associated vasculitis according to the protocol for the rat 
model. For this purpose, BALB/c, NZW, B6/N, B6/J, and DBA 
mice (n = 5/strain) were given i.p. injection of PMA (50 ng at 
days 0 and 7) and oral PTU (2.5 mg/day) for 4 weeks (Figure 2A). 
The serum titers of MPO-ANCA at day 28 were 100.4 ± 12.0 ng/
ml in BALB/c, 96.1 ±  12.8  ng/ml in NZW, 41.3 ±  0.90  ng/ml 
in B6/N, 31.6 ±  5.79 ng/ml in B6/J, and 32.0 ±  4.06 ng/ml in 
DBA mice (Figure 2B). Contrary to the rat model, no vasculitic 
lesion was observed in the lungs and kidneys of all mouse strains 
examined. Correspondingly, renal dysfunction was not detected 
in the urine and blood samples. Based on these findings, we 
employed BALB/c mice to construct the mouse model with 
MPO-ANCA production. The serum MPO-ANCA titer at day 
14 was 79.0 ± 5.70 ng/ml in the BALB/c model. MPO-ANCA 
was not detected in the vehicle-injected BALB/c mice.
effect of PaD inhibitor on citrullination 
In Vivo
BALB/c mice (14-week-old female) were given i.p. injection of 
PMA (50  ng at days 0 and 7) and oral PTU (2.5  mg/day) for 
2 weeks. These mice were divided into two groups. The first group 
was given daily i.p. injection of PBS (200 μl/day) (n = 13) and the 
other group with daily i.p. injection of Cl-amidine (0.3 mg/200 μl 
PBS/day) (n = 7) (Figure 3A). At day 14, the peritoneal tissues 
were subjected to immunohistochemistry for citrullinated his-
tone 3 for the evaluation of NET formation in vivo. As a result, 
the rate of citrullinated histone 3-positive cells in polymorpho-
nuclear cells was significantly reduced in the Cl-amidine-treated 
mice in comparison with the vehicle-injected control mice (38% 
reduction) (Figure 3B).
effect of PaD inhibitor on MPO-anca 
Production In Vivo
The serum titers of MPO-ANCA in the Cl-amidine-treated mice 
(32.3 ±  31.0  ng/ml) were significantly lower than the vehicle-
injected control mice (132.1 ± 41.6 ng/ml) (Figure 3C). The col-
lective findings clearly indicate that NET formation is inhibited 
by the pan-PAD inhibitor, Cl-amidine, both in vitro and in vivo, 
and that MPO-ANCA production is suppressed by Cl-amidine 
in vivo.
DiscUssiOn
The PMA-stimulated neutrophils extrude decondensated DNA, 
which forms extracellular web-like structures decorated with 
bactericidal proteins (7). Since this substance, called NETs, can 
bind and kill bacteria, NET formation is regarded as an important 
event in innate immunity. Chronic granulomatous disease (CGD) 
patients who cannot generate NETs are susceptible to diverse 
bacteria and fungi indeed, and it was shown that restoration of 
NET formation in CGD resulted in resistance to such infections 
(28). Currently, it is considered that NET appears to be a form of 
innate response that binds microorganisms, prevents them from 
spreading, and ensures a high local concentration of antimicro-
bial agents derived from neutrophils (29).
The PMA-stimulated neutrophils undergo cell death with 
NET formation (8). Since the characteristics of cell death 
resembled neither typical necrosis nor apoptosis, Steinberg et al. 
coined NETosis for the neutrophil death with NET formation 
(30). However, Clark et al. have demonstrated that neutrophils 
do not necessarily undergo cell death after NET formation (31). 
It has been shown that NET formation can occur with preser-
vation of neutrophilic functions, including phagocytosis and 
FigUre 3 | effect of cl-amidine on citrullination and MPO-anca production in vivo. Experimental protocol (a). BALB/c mice (14-week-old female) were 
given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks (p.o.: Per Os). These mice were divided into two groups. The first group of 
mice was given daily i.p. injection of PBS (200 μl/day) (n = 13). The other group was given daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (n = 7). Mouse 
urine was collected during the last 24 h using metabolic cages. Blood and tissue samples were obtained at day 14. NET formation in peritoneal tissues (B). The 
formalin-fixed paraffin-embedded sections of peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3. Representative photos among 
five random fields of view (×100) were shown. NET induction was quantified by calculating the rate of citrullinated histone 3-positive cells in polymorphonuclear cells 
in the five random fields of view. *p < 0.05 in Mann–Whitney U-test. Serum titers of MPO-ANCA determined by ELISA (c). **p < 0.01 in Mann–Whitney U-test.
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chemotaxis (10, 11). This phenomenon termed vital NETosis (9). 
On the contrary, aforementioned dying NETosis has been called 
suicidal NETosis.
Although NETs play an essential role in the innate immu-
nity, some harmful aspects of NETs have been demonstrated 
(32, 33). They not only have direct cytotoxic and thrombotic 
effects on vascular endothelium (12–14), but NETs are also 
associated with pathogenic autoantibody production (5, 17). 
For example, impairment of NET degradation potential (low 
activity of DNase I) in the serum is present in 30–40% of patients 
with SLE and is suggested to lead the production of anti-DNA 
antibodies, which are related to disease severity (17). In another 
case, morphologically abnormal and DNase I-resistant NETs are 
generated by the anti-thyroid drug, PTU, and then MPO in the 
NETs seems to be recognized by the immune system resulting 
in the production of MPO-ANCA in rats administered with 
PTU (5). It has been shown that a part of PTU is metabolized 
by  MPO. Simultaneously, conformational alteration of MPO 
could be induced by PTU (34), which could result in the toler-
ance break to MPO.
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In the present study, we established mouse models with 
MPO-ANCA production. We treated five strains of mouse with 
PMA and PTU corresponding to the previously established 
protocol for the rat model of MPO-ANCA-associated vasculitis. 
Interestingly, there was a strain-dependency in the response to 
produce MPO-ANCA in mouse. Although the precise mecha-
nism of the strain-dependency has to be determined in future 
studies, the Th2 phenotype of BALB/c (35) and autoimmune-
prone genetic background of NZW (36) may be associated 
with the susceptibility to produce autoantibodies. In addition, 
no vasculitic lesion was observed in the mouse models with 
MPO-ANCA production, whereas WKY rats with MPO-ANCA 
developed pulmonary capillaritis and glomerulonephritis (5). 
Species-dependency may be present in the development of 
PMA plus PTU-induced MPO-ANCA-associated vasculitis. 
Nonetheless, we employed BALB/c mice to construct in  vivo 
models of MPO-ANCA production.
Neeli et al. first demonstrated that PAD4-dependent histone 
deimination occurred in activated neutrophils under inflamma-
tory conditions (37). Since PAD4-deficient neutrophils did not 
generate NETs in response to PMA, PAD4 plays a pivotal role in the 
NET formation (23). Correspondingly, inhibition of PAD4 using 
the pan-PAD inhibitor, Cl-amidine, prevented citrullination of 
histone 3 and significantly reduced NET release from HL60 cells, 
which were differentiated into mature neutrophils, in response 
to Ca2+ ionophore or Shigella flexneri exposure (24). In addition, 
Cl-amidine has been shown to suppress NET formation in lupus-
prone mice (27). It has been shown that Cl-amidine can modify 
the cysteine of PAD and then inactivate it irreversibly (38). Based 
on these findings, we conducted in vitro and in vivo experiments 
to inhibit citrullination/NET formation using Cl-amidine as a 
pan-PAD inhibitor. The present study reproduced and extended 
the results of previous reports that investigated Cl-amidine both 
in vitro and in vivo and demonstrated that MPO-ANCA produc-
tion was suppressed by Cl-amidine in vivo. These findings suggest 
that excessive formation of NETs may be implicated in MPO-
ANCA production in  vivo. In order to demonstrate the direct 
implication of PAD4-dependent NET formation in MPO-ANCA 
production, further studies using PAD4-deficient mice should be 
designed.
One limitation of this study is the lack of quantification of 
released NETs, which can be usually detected as MPO-DNA com-
plexes in the serum. However, it has been shown that the PMA 
plus PTU-induced NETs hardly converted into soluble form (5). 
Thus, there is no better methodology to evaluate NETs in the 
murine model than the immunohistochemistry for  citrullinated 
histone 3.
No vasculitic phenotype was observed in the PMA plus 
PTU-induced mouse models with MPO-ANCA production. 
Therefore, we could not examine the effect of PAD inhibitors 
on MPO-ANCA-associated vasculitis in this model, which is 
another limitation of this study. It should be determined whether 
increased doses of PMA/PTU and/or longer duration could 
induce vasculitis in the mouse models in future studies.
It has been shown that MPO-ANCA is the major pathogenic 
factor in MPO-ANCA-associated vasculitis (2, 3). Thus, it is 
expected that PAD inhibitors, which can suppress the produc-
tion of the pathogenic autoantibody, would be applied for the 
treatment of patients with MPO-ANCA-associated vasculitis. 
Preceding studies have demonstrated the protective effects of 
PAD inhibitors on the models of SLE (27) and other NET-related 
diseases, including multiple sclerosis (39), collagen-induced 
arthritis (40), and inflammatory bowel disease (41). Although 
further studies are needed to clarify their safety and effective-
ness, PAD inhibitors are potential candidates as novel therapeutic 
agents for various NET-related diseases, including MPO-ANCA-
associated vasculitis.
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